By: IPP Bureau
Last updated : May 12, 2026 7:54 am
The company’s PAT rose 43.7% year-on-year to Rs. 45.3 crore in Q4FY26 from Rs. 31.5 crore
CORONA Remedies Limited announced its audited financial results for Q4FY26 and FY26, reporting strong growth supported by focused brand-building initiatives, portfolio expansion, and operational efficiencies.
The company’s revenue from operations grew 20.2% year-on-year to Rs. 353.1 crore in Q4FY26, compared to Rs. 293.7 crore in the corresponding quarter last year. For the full fiscal year, revenue increased 17.3% to Rs. 1,403.2 crore from Rs. 1,196.4 crore in FY25.
EBITDA for Q4FY26 stood at Rs. 62 crore, up 14.4% from Rs. 54.2 crore a year earlier, while FY26 EBITDA rose 22.3% to Rs. 293.4 crore from Rs. 240 crore in FY25. EBITDA margins stood at 17.6% for Q4FY26 and 20.9% for FY26.
While FY26 PAT increased 33.4% to Rs. 199.4 crore compared to Rs. 149.4 crore in the previous fiscal. The FY26 numbers include a one-time statutory impact related to the New Labor Code amounting to Rs. 19.1 crore (post-tax impact of Rs. 14.3 crore).
During the year, the company acquired WOKADINE, marking its entry into the Rs. 648 crore Povidone Iodine market. The acquisition was funded through internal accruals. CORONA Remedies also expanded its portfolio through the relaunch of brands including Fostine R and Menodac under women’s health therapeutics, and Noklot in the cardiovascular segment.
Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said, ‘Our strategic focus on brand building, specialty segments like biosimilars and infertility and portfolio expansion through acquisitions continues to strengthen our competitive positioning. With strategic initiatives like acquisition of WOKADINE and global accreditations, we are well-positioned to drive sustainable growth in years to come.’